Eraxis is a drug owned by Vicuron Holdings Llc. It is protected by 3 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 22, 2023. Details of Eraxis's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7709444 | Echinocandin pharmaceutical formulations containing micelle-forming surfactants |
Apr, 2021
(4 years ago) |
Expired
|
| US6960564 | Echinocandin pharmaceutical formulations containing micelle-forming surfactants |
Apr, 2021
(4 years ago) |
Expired
|
| US5965525 | Cyclic peptide antifungal agents |
Feb, 2020
(5 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Eraxis's patents.
Latest Legal Activities on Eraxis's Patents
Given below is the list of recent legal activities going on the following patents of Eraxis.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent
Critical | 06 Jun, 2022 | US7709444 |
| Maintenance Fee Reminder Mailed
Critical | 20 Dec, 2021 | US7709444 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 16 Oct, 2017 | US7709444 |
| Correspondence Address Change
Critical | 23 Aug, 2010 | US7709444 |
| Post Issue Communication - Certificate of Correction | 10 Aug, 2010 | US7709444 |
| Email Notification
Critical | 27 Jul, 2010 | US7709444 |
| Mail-Record a Petition Decision of Granted to Issue Patent in Name of the Assignee | 20 Jul, 2010 | US7709444 |
| Record a Petition Decision of Granted to Issue Patent in Name of the Assignee | 19 Jul, 2010 | US7709444 |
| Petition Entered | 14 Jun, 2010 | US7709444 |
| Post Issue Communication - Certificate of Correction Denied | 16 May, 2010 | US7709444 |
FDA has granted several exclusivities to Eraxis. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Eraxis, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Eraxis.
Exclusivity Information
Eraxis holds 1 exclusivities. All of its exclusivities have expired in 2023. Details of Eraxis's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 22, 2023 |
US patents provide insights into the exclusivity only within the United States, but
Eraxis is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Eraxis's family patents as well as insights into
ongoing legal events
on those patents.
Eraxis's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Eraxis's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Sep 22, 2023 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Eraxis Generics:
There are no approved generic versions for Eraxis as of now.
Alternative Brands for Eraxis
Eraxis which is used for treating fungal infections., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
About Eraxis
Eraxis is a drug owned by Vicuron Holdings Llc. It is used for treating fungal infections. Eraxis uses Anidulafungin as an active ingredient. Eraxis was launched by Vicuron Holdings in 2006.
Approval Date:
Eraxis was approved by FDA for market use on 17 February, 2006.
Active Ingredient:
Eraxis uses Anidulafungin as the active ingredient. Check out other Drugs and Companies using Anidulafungin ingredient
Treatment:
Eraxis is used for treating fungal infections.
Dosage:
Eraxis is available in powder form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 100MG/VIAL | POWDER | Prescription | INTRAVENOUS |
| 50MG/VIAL | POWDER | Prescription | INTRAVENOUS |